NEW YORK, March 19, 2018 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage
biopharmaceutical company developing novel oncology therapeutics, announced today that Ivan Bergstein, M.D., Stemline’s CEO, will
present at the Oppenheimer 28th Annual Healthcare Conference on Wednesday, March 21, 2018 at 3:20 PM ET at the Westin
New York Grand Central. A live webcast of the presentation can be viewed on the company's website at www.stemline.com.
About Stemline Therapeutics
Stemline Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel oncology therapeutics. Stemline is
developing three clinical stage product candidates, SL-401, SL-801, and SL-701. SL-401 is a targeted therapy directed to the
interleukin-3 receptor (CD123) present on a range of malignancies. SL-401 has completed a pivotal trial in blastic plasmacytoid
dendritic cell neoplasm (BPDCN), for which it was granted breakthrough therapy designation (BTD). The pivotal trial met its primary
endpoint and a BLA filing is in preparation. SL-401 is also being evaluated in clinical trials in additional indications including
chronic myelomonocytic leukemia (CMML), myelofibrosis (MF), acute myeloid leukemia (AML), and myeloma. SL-801 is a novel oral small
molecule reversible inhibitor of XPO1 that is currently in a Phase 1 trial of patients with advanced solid tumors; dose escalation
is ongoing. SL-701, an immunotherapeutic, has completed a Phase 2 trial in patients with second-line glioblastoma; data and next
steps for the program are being evaluated.
Forward-Looking Statements
Some of the statements included in this press release may be forward-looking statements that involve a number of risks and
uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the
Private Securities Litigation Reform Act of 1995. The factors that could cause our actual results to differ materially include: the
intended use of proceeds from the offering; the success and timing of our clinical trials and preclinical studies for our product
candidates, including site initiation, institutional review board approval, scientific review committee approval, patient accrual,
safety, tolerability and efficacy data observed, and input from regulatory authorities including the risk that the FDA or other
ex-U.S. national drug authority ultimately does not agree with our data, find our data supportive of approval, or approve any
of our product candidates; our plans to develop and commercialize our product candidates; market acceptance of our products;
reimbursement available for our products; our available cash and investments; our ability to obtain and maintain intellectual
property protection for our product candidates; our ability to obtain and maintain intellectual property protection for our product
candidates; our ability to manufacture; the performance of third-party manufacturers, clinical research organizations, clinical
trial sponsors and clinical trial investigators; and other risk factors identified from time to time in our reports filed with the
SEC. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not
intend to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof.
Contact
Investor Relations
Stemline Therapeutics, Inc.
750 Lexington Avenue
Eleventh Floor
New York, NY 10022
Tel: 646-502-2307
Email: investorrelations@stemline.com
